AR014012A1 - Formula de liberacion prolongada - Google Patents

Formula de liberacion prolongada

Info

Publication number
AR014012A1
AR014012A1 ARP980105563A ARP980105563A AR014012A1 AR 014012 A1 AR014012 A1 AR 014012A1 AR P980105563 A ARP980105563 A AR P980105563A AR P980105563 A ARP980105563 A AR P980105563A AR 014012 A1 AR014012 A1 AR 014012A1
Authority
AR
Argentina
Prior art keywords
venlafaxine hydrochloride
extended
release form
prolonged release
offers
Prior art date
Application number
ARP980105563A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25508423&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR014012(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR014012A1 publication Critical patent/AR014012A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invencion se relaciona con una formula posologica y dosis unitaria de la misma, de clorhidrato de venlafaxina, un agente antidepresivo,de liberacion prolongada sobre 24 horas, que ofrece un control mejor de las concentraciones plasmáticas que el de las formulas convencionales en tabletasque deben administrarse dos o más veces al día, y que también se asocia con una incidencia menor de náuseas y vomitos que las tabletas convencionales. En suaspecto primario, esta invencion ofrece un nucleo mejorado de los esferoides de liberacion prolongada, que comprende clorhidrato de venlafaxina y celulosamicrocistalina, es decir, sin el agregado de hidroxipropilmetilcelulosa.
ARP980105563A 1997-11-05 1998-11-04 Formula de liberacion prolongada AR014012A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US96432897A 1997-11-05 1997-11-05

Publications (1)

Publication Number Publication Date
AR014012A1 true AR014012A1 (es) 2001-01-31

Family

ID=25508423

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980105563A AR014012A1 (es) 1997-11-05 1998-11-04 Formula de liberacion prolongada

Country Status (39)

Country Link
EP (1) EP1028718B1 (es)
JP (1) JP2001521892A (es)
KR (1) KR20010031797A (es)
CN (1) CN1278165A (es)
AR (1) AR014012A1 (es)
AT (1) ATE237320T1 (es)
AU (1) AU747978B2 (es)
BG (1) BG104397A (es)
BR (1) BR9813179A (es)
CA (1) CA2305242A1 (es)
CL (1) CL2004001705A1 (es)
CO (1) CO5011060A1 (es)
CZ (1) CZ20001659A3 (es)
DE (1) DE69813602T2 (es)
DK (1) DK1028718T3 (es)
EA (1) EA200000487A1 (es)
EE (1) EE04577B1 (es)
ES (1) ES2196620T3 (es)
GE (1) GEP20043198B (es)
HK (1) HK1029056A1 (es)
HR (1) HRP20000213B1 (es)
HU (1) HU225238B1 (es)
ID (1) ID26317A (es)
IL (1) IL135457A0 (es)
MA (1) MA24691A1 (es)
NO (1) NO20002126L (es)
NZ (1) NZ504460A (es)
PA (1) PA8462501A1 (es)
PE (1) PE128699A1 (es)
PL (1) PL341141A1 (es)
PT (1) PT1028718E (es)
SK (1) SK6472000A3 (es)
SV (1) SV1998000131A (es)
TR (1) TR200001232T2 (es)
TW (1) TW555568B (es)
UA (1) UA77145C2 (es)
UY (2) UY25234A1 (es)
WO (1) WO1999022724A2 (es)
ZA (1) ZA9810081B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2368083A1 (en) * 1999-04-06 2000-10-12 Sepracor Inc. Derivatives of venlafaxine and methods of preparing and using the same
DE60035579T2 (de) * 1999-05-20 2008-04-17 Elan Corp. Plc Multipartikuläre arzneizusammensetzungen mit gesteuerter wirkstoffabgabe enthaltend selektive inhibitoren der serotoninwiederaufnahme
IL146462A (en) * 2001-11-13 2015-02-26 Lycored Bio Ltd Prolonged-release preparations containing as an active compound and analapaxin hydrochloride
EP1451145A1 (en) * 2001-12-05 2004-09-01 Wyeth Novel crystalline polymorph of venlafaxine hydrochloride and methods for the preparation thereof
WO2003050074A1 (en) * 2001-12-13 2003-06-19 Cadila Healthcare Limited Manufacture of venlafaxine hydrochloride and crystalline polymorphs thereof
WO2003055475A1 (en) * 2002-01-03 2003-07-10 Lek Pharmaceutical And Chemical Company D.D. Controlled release pharmaceutical formulation containing venlafaxine
EP1485344A1 (en) 2002-03-28 2004-12-15 Synthon B.V. Venlafaxine besylate
AU2003226752A1 (en) * 2002-03-28 2003-10-13 Synthon B.V. Venlafaxine base
US6696496B2 (en) 2002-03-28 2004-02-24 Synthon Bv Low water-soluble venlafaxine salts
AU2003219117A1 (en) * 2002-03-28 2003-10-13 Synthon B.V. Extended release venlafaxine formulations
FR2845289B1 (fr) 2002-10-04 2004-12-03 Ethypharm Sa Spheroides, procede de preparation et compositions pharmaceutiques.
CA2415154C (en) * 2002-12-24 2009-06-16 Biovail Laboratories Inc. Modified release formulations of selective serotonin re-uptake inhibitors
DE10350194B4 (de) * 2003-10-28 2005-11-10 Bioplanta Arzneimittel Gmbh Verwendung von Extrakten aus Opuntien zur Behandlung von depressiven Verstimmungen und Erkrankungen
TW200503670A (en) * 2003-03-28 2005-02-01 Sandoz Ag Venlafaxine compositions
EP1502587B1 (en) * 2003-07-30 2006-08-23 Pharmathen S.A. Sustained release formulation for Venlafaxine hydrochloride
HUP0303382A2 (hu) * 2003-10-10 2005-08-29 EGIS Gyógyszergyár Rt. Venlafaxin-hidroklorid-tartalmú pelletek
JP2007520547A (ja) 2004-02-04 2007-07-26 アレムビック・リミテッド ベンラファキシン塩酸塩の徐放性コーティングされた小型錠剤
US7776358B2 (en) 2004-07-22 2010-08-17 Synthon Ip Inc. Extended release venlafaxine besylate tablets
US20190083399A9 (en) * 2006-04-03 2019-03-21 Isa Odidi Drug delivery composition
WO2007129329A2 (en) * 2006-05-08 2007-11-15 Jubilant Organosys Limited Extended release pharmaceutical formulation comprising venlafaxine hydrochloride
CN102772390B (zh) * 2012-08-16 2014-01-08 乐普药业股份有限公司 一种盐酸文拉法辛缓释胶囊及其制备方法
FR3080278B1 (fr) * 2018-04-11 2021-04-30 Ghs Patents Ltd Procede de fabrication d'un spheroide de cannabidiol

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1561204A (en) * 1977-06-01 1980-02-13 Ici Ltd Sustained release pharmaceutical composition
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
PE57198A1 (es) * 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
ZA97976B (en) * 1996-04-05 1997-08-18 Alza Corp Uniform drug delivery theraphy.

Also Published As

Publication number Publication date
ZA9810081B (en) 2000-05-04
GEP20043198B (en) 2004-03-25
KR20010031797A (ko) 2001-04-16
NO20002126D0 (no) 2000-04-26
TW555568B (en) 2003-10-01
ES2196620T3 (es) 2003-12-16
TR200001232T2 (tr) 2000-12-21
CZ20001659A3 (cs) 2001-10-17
ID26317A (id) 2000-12-14
DE69813602T2 (de) 2003-11-06
EP1028718A2 (en) 2000-08-23
MA24691A1 (fr) 1999-07-01
HRP20000213A2 (en) 2000-12-31
WO1999022724A2 (en) 1999-05-14
AU747978B2 (en) 2002-05-30
PA8462501A1 (es) 2000-05-24
HU225238B1 (en) 2006-08-28
DK1028718T3 (da) 2003-07-28
ATE237320T1 (de) 2003-05-15
HRP20000213B1 (en) 2004-04-30
SK6472000A3 (en) 2000-11-07
AU1300399A (en) 1999-05-24
UA77145C2 (en) 2006-11-15
BR9813179A (pt) 2000-08-22
UY25234A1 (es) 2000-12-29
HUP0004287A3 (en) 2002-05-28
WO1999022724A3 (en) 1999-07-22
HUP0004287A2 (hu) 2002-04-29
CL2004001705A1 (es) 2005-06-03
PT1028718E (pt) 2003-07-31
JP2001521892A (ja) 2001-11-13
HK1029056A1 (en) 2001-03-23
EE200000212A (et) 2001-04-16
CN1278165A (zh) 2000-12-27
CO5011060A1 (es) 2001-02-28
IL135457A0 (en) 2001-05-20
EP1028718B1 (en) 2003-04-16
EA200000487A1 (ru) 2000-10-30
NZ504460A (en) 2003-01-31
NO20002126L (no) 2000-05-04
BG104397A (en) 2001-02-28
CA2305242A1 (en) 1999-05-14
SV1998000131A (es) 1999-11-18
EE04577B1 (et) 2006-02-15
PE128699A1 (es) 2000-01-06
PL341141A1 (en) 2001-03-26
UY25692A1 (es) 2000-03-31
DE69813602D1 (de) 2003-05-22

Similar Documents

Publication Publication Date Title
AR014012A1 (es) Formula de liberacion prolongada
UY24613A1 (es) Formula de liberacion controlada que comprende venlafaxina
MX2007006212A (es) Medicamento oral para liberacion modificada de al menos un principio activo bajo forma multimicrocapsular.
NO20011471D0 (no) Nye orale vedvarende frigivelsesformuleringer
AR004179A1 (es) Sales de (endo,sin)-(-)-3-(3-hidroxi-1-oxo-2-fenilpropoxi)-8-metil-8-(1- metiletil)-8-azoniabiciclo[3.2.1] octano y preparaciones medicamentosasinhalativas que las contienen.
PA8481601A1 (es) Desnaturalizantes para las sales aminas simpaticomimeticas
AR012927A1 (es) Una composicion farmaceutica, una forma de dosificacion farmaceutica, el uso de dicha composicion para la fabricacion de un medicamento y una forma depresentacion farmaceutica adecuada para la venta comercial
ATE460157T1 (de) Pharmazeutische metformintablette mit verlängerter freisetzung
NO20053106L (no) Oral, analgesisk doseringsform med forlenget frigivelse.
AR011114A1 (es) COMPOSICIoN FARMACÉUTICA LIBRE DE LACTOSA EN FORMA GRANULADA O EN MEZCLA PARA EL TRATAMIENTO DE DESoRDENES INDUCIDOS POR HISTAMINA.
ES2191987T3 (es) Formas de dosificacion de ribavirina solidas, administrables oralmente, y procedimiento de fabricacion.
ES2176106B1 (es) Comprimido matricial de liberacion prolongada de trimetazidina tras su administracion por via oral.
CO6150128A2 (es) Formulacion de nevirapina de liberacion prolongada
ES2305567T3 (es) Formulaciones de tramadol de liberacion sostenida con una eficacia de 24 horas.
ES2171459T3 (es) Polvo para administracion nasal de farmaco peptidico o proteinaceo.
AR038373A1 (es) Sistema de suministro osmotico
TR200200978T2 (tr) Yeni mirtazapin formülasyonu
ECSP972046A (es) Formula de liberacion prolongada
ECSP982704A (es) Formula de liberacion prolongada
ATE301469T1 (de) Pharmazeutische diclofenac-verbindung basierend auf vitamin e, papain und hyaluronidase
MX9203068A (es) Compuestos activirales oralmente activos.
AR034505A1 (es) Composiciones medicinales y proceso de manufactura
GT199800103A (es) Sales de sertralina y formas de dosificacion de liberacion sostenida de sertralina.
ECSP982436A (es) Composicion
PE20020893A1 (es) Composiciones farmaceuticas que comprende pravastatina

Legal Events

Date Code Title Description
FB Suspension of granting procedure